Introduction
All you need to know about FIBURIK 120mg .
Welcome to Dwaey, specifically on FIBURIK 120mg page.
This medicine contains an important and useful components, as it consists of Febuxostat.
FIBURIK 120mg is available in the market in concentration 120 mg/Tablet and in the form of Tablets/Film-coated.
NEOPHARMA is the producer of FIBURIK 120mg and it is imported from UAE, The most popular alternatives of FIBURIK 120mg are listed downward .
-
Active Substance
Febuxostat
-
Size
30Õs (10Õs Blister ? 3)
-
Indications
-
Type
Tablets/Film-coated
-
Company
NEOPHARMA
Frequently Asked Questions
FIBURIK 120mg should be stored according to the instructions provided by NEOPHARMA.
In general, it is recommended to store FIBURIK 120mg in a cool, dry place, away from direct sunlight
and out of the reach of children.
The duration of treatment with FIBURIK 120mg may vary depending on the condition being treated
and the guidance of your healthcare provider. It is important to follow the prescribed treatment
plan and continue taking FIBURIK 120mg for the recommended duration, even if your symptoms improve.
If you have any concerns or questions about the duration of treatment, consult your healthcare provider.
It is important to check with your healthcare provider or read the medication label for specific
instructions regarding alcohol consumption while taking FIBURIK 120mg . Some medications, including
FIBURIK 120mg , may have interactions with alcohol that can reduce effectiveness, increase side
effects, or pose other risks to your health. It is best to follow the guidance provided by your
healthcare professional.
If you miss a dose of FIBURIK 120mg , take it as soon as you remember. However, if it is close
to the time for your next scheduled dose, skip the missed dose and continue with your regular dosing
schedule. Do not take a double dose to make up for a missed one unless advised by your healthcare provider.
No, do not stop taking FIBURIK 120mg without consulting your healthcare provider, even if your
symptoms improve. It is important to complete the full course of treatment as prescribed. Stopping
the medication prematurely may lead to a relapse or incomplete resolution of the condition. If you
have concerns about the duration of treatment, consult your healthcare provider for guidance.
It is important to consult your healthcare provider before taking FIBURIK 120mg if you are
pregnant or breastfeeding. They will be able to assess the potential risks and benefits based on your
specific situation. Please note that the safety and suitability of FIBURIK 120mg during pregnancy
or breastfeeding may depend on the active substance [Active Substance], concentration 120 mg/Tablet,
and the specific recommendations of NEOPHARMA.
The effects of FIBURIK 120mg on your ability to drive or operate machinery can vary depending on
the active substance [Active Substance], concentration 120 mg/Tablet, and individual factors.
Some medications may cause drowsiness, dizziness, or other side effects that can impair your judgment
or coordination. It is important to read the medication label or consult your healthcare provider to
understand any potential effects on your ability to perform tasks that require alertness.
The instructions for taking FIBURIK 120mg with or without food may vary depending on the medication
and the recommendations of NEOPHARMA. Some medications may be more effective when taken with
food to enhance absorption or reduce stomach irritation, while others may need to be taken on an empty
stomach for optimal absorption. Read the medication label or consult your healthcare provider for specific instructions.
The use of FIBURIK 120mg in children or elderly individuals may depend on various factors, including
the specific medication, type Tablets/Film-coated, and the recommendations of NEOPHARMA. Some
medications may have specific dosing instructions or precautions for these age groups. Consult your
healthcare provider or read the medication label for information regarding the safe and appropriate use
of FIBURIK 120mg in children or elderly individuals.
0 Comments